Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
In order to acquire both expanded binding ability with the EphA2 receptor and superior drug delivery capacity, we designed and synthesized the modified GO-SWL-Ahx-K-SWL conjugate as a potential targeted therapeutic drug for non-small cell lung cancer (NSCLC). Various characterization methods have confirmed that the conjugate is consistent with the theoretical peptide. The cytotoxicity test results showed that the conjugate was slightly more toxic to A549 cells than in 3 T3 cells, and the toxicity increased in a concentration-dependent manner. Single photon emission computed tomography/computed tomography (SPECT/CT) fusion imaging was performed to evaluate the conjugate binding to EphA2 receptor in vivo. The images showed obvious radioactive concentration in tumor tissues and significantly higher ratios of the tumor and muscle in the I-GO-SWL-Ahx-K-SWL group (10.78) than in the I-SWL-Ahx-K-SWL group (5.21) at all three time points (P < 0.01).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2022.128802 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tumor-Specific EphA2 Receptor Tyrosine Kinase Inhibits Anti-Tumor Immunity by Recruiting Suppressive Myeloid Populations in Murine Models of Non-Small Cell Lung Cancer.
Cancers (Basel)
August 2025
Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37235, USA.
Background: EphA2 is a receptor tyrosine kinase that contributes to tumor growth and metastasis and has been identified as a viable target for many solid cancers. Investigating EphA2's impact on the host immune system may advance our understanding of tumor immune evasion and the consequences of targeting EphA2 on the tumor microenvironment.
Methods: Here, we examine how tumor-specific EphA2 affects the activation and infiltration of immune cell populations and the cytokine and chemokine milieu in murine models of non-small cell lung cancer (NSCLC).
Bayesian analysis and efficient algorithms for single-molecule fluorescence data and step counting.
Biophys J
August 2025
Department of Mathematics, University of Tennessee, Knoxville, TN. Electronic address:
With the growing adoption of single-molecule fluorescence experiments, there is an increasing demand for efficient statistical methodologies and accurate analysis of the acquired measurements. Existing analysis frameworks, such as those that use kinetic models, often rely on strong assumptions on the dynamics of the molecules and fluorophores under study that render them inappropriate for general purpose step counting applications, especially when the systems of study exhibit uncharacterized dynamics. Here, we propose a novel Bayesian nonparametric framework to analyze single-molecule fluorescence data that is kinetic model independent.
View Article and Find Full Text PDFTissue microarray and liquid biopsy approaches identify EphB3, cMet, and miR-3168 as biomarkers of colorectal cancer.
Cell Cycle
September 2025
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Colorectal cancer (CRC) remains a significant global health concern, and reliable biomarkers are needed to improve early diagnosis, prognostication, and personalized treatment strategies. This study investigated the expression of cell surface proteins and serum exosomal miRNAs in CRC patients. Tissue microarrays (TMAs) constructed from primary and metastatic CRC samples were analyzed for five cell surface proteins: EphB1, EphB3, EphA2, cMet, and EphB4.
View Article and Find Full Text PDFA Tumor-Specific Membrane Protein Degradation Platform via Covalent Reaction-Induced Aggregation.
ACS Appl Mater Interfaces
August 2025
CAS Center for Excellence in Nanoscience, Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), Beijing 100190, China.
The majority of lysosome-targeting degradation strategies for membrane proteins rely on recruiting specific lysosome-targeting receptors; however, the low expression levels of these receptors in tumor cells limit their further applications. Herein, we design covalent membrane protein aggregate-targeting chimeras, termed CMPATACs, for tumor-specific membrane protein degradation, which do not rely on specific receptors. We first utilized a covalent reaction to irreversibly bind specific membrane proteins, and this process facilitates the formation of membrane protein aggregates that enter the lysosome for degradation, leading to improved anticancer capacity.
View Article and Find Full Text PDFEphA2 and Ephrin-A1 Utilize the Same Interface for Both and Interactions That Differentially Regulate Cell Signaling and Function.
bioRxiv
August 2025
Division of Cancer Biology, Department of Medicine, MetroHealth Center for Cancer Research, MetroHealth Campus, Case Western Reserve University, Cleveland, OH, United States.
The 14 members of Eph receptor tyrosine kinases (RTK) bind to membrane-tethered ligand called ephrins and mediate cell contact signaling where the receptors and ligands engage on adjacent cells. Previous studies reveal that some Eph and ephrin pairs are coexpressed on the same cells, including EphA3-ephrin-A3 and EphA4/ephrin-A5, can also interact with each other . However, significant discrepancies persist as to the molecular basis and functional significance of the interactions, owning to the difficulties to directly interrogate the interactions.
View Article and Find Full Text PDF